JY09
/ Beijing Eastern Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 9
Of
9
Go to page
1
September 19, 2025
DFBT-JY09-DM-301: A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients
(clinicaltrials.gov)
- P3 | N=270 | Active, not recruiting | Sponsor: Beijing Dongfang Biotech Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Jun 2026 | Trial primary completion date: Apr 2025 ➔ May 2026
Enrollment closed • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
September 18, 2025
DFBT-JY09-DM-302: A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin
(clinicaltrials.gov)
- P3 | N=600 | Active, not recruiting | Sponsor: Beijing Dongfang Biotech Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Nov 2026 | Trial primary completion date: Apr 2025 ➔ Oct 2026
Enrollment closed • Trial completion date • Trial primary completion date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
August 22, 2024
DFBT-JY09-DM-302: A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin
(clinicaltrials.gov)
- P3 | N=600 | Recruiting | Sponsor: Beijing Dongfang Biotech Co., Ltd. | Not yet recruiting ➔ Recruiting | Initiation date: Mar 2024 ➔ Jul 2024
Combination therapy • Enrollment open • Trial initiation date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
August 21, 2024
Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects
(clinicaltrials.gov)
- P1 | N=28 | Completed | Sponsor: Beijing Dongfang Biotech Co., Ltd. | Active, not recruiting ➔ Completed
Trial completion • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus
August 20, 2024
DFBT-JY09-DM-301: A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients
(clinicaltrials.gov)
- P3 | N=270 | Recruiting | Sponsor: Beijing Dongfang Biotech Co., Ltd. | Not yet recruiting ➔ Recruiting | Initiation date: Mar 2024 ➔ Jul 2024
Enrollment open • Trial initiation date • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
February 16, 2024
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin
(clinicaltrials.gov)
- P3 | N=600 | Not yet recruiting | Sponsor: Beijing Dongfang Biotech Co., Ltd.
Combination therapy • New P3 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
February 16, 2024
DFBT-JY09-DM-301: A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients
(clinicaltrials.gov)
- P3 | N=270 | Not yet recruiting | Sponsor: Beijing Dongfang Biotech Co., Ltd.
New P3 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
February 08, 2024
Influence of JY09 on Pharmacokinetics of Metformin , Rosuvastatin , and Digoxin and the QT Interval Study in Overweight Chinese Subjects
(clinicaltrials.gov)
- P1 | N=28 | Active, not recruiting | Sponsor: Beijing Dongfang Biotech Co., Ltd.
New P1 trial • Diabetes • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus
April 21, 2020
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JY09
(clinicaltrials.gov)
- P1; N=41; Completed; Sponsor: Beijing Dongfang Biotech Co., Ltd.
Clinical • New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
1 to 9
Of
9
Go to page
1